syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Company profile
Ticker
SYRS
Exchange
Website
CEO
Nancy Simonian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LS22, Inc.
SEC CIK
Corporate docs
Subsidiaries
Syros Securities Corporation • Syros Pharmaceuticals (Ireland) Limited • Tyme Technologies, Inc. • Tyme, Inc. ...
SYRS stock data
Latest filings (excl ownership)
8-K
Termination of a Material Definitive Agreement
11 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Termination of a Material Definitive Agreement
21 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
8-K
Regulation FD Disclosure
25 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
424B5
Prospectus supplement for primary offering
1 May 23
EFFECT
Notice of effectiveness
1 May 23
CORRESP
Correspondence with SEC
26 Apr 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
Transcripts
SYRS
Earnings call transcript
2023 Q2
8 Aug 23
SYRS
Earnings call transcript
2023 Q1
10 May 23
SYRS
Earnings call transcript
2022 Q4
2 Mar 23
SYRS
Earnings call transcript
2022 Q3
14 Nov 22
SYRS
Earnings call transcript
2022 Q2
9 Aug 22
SYRS
Earnings call transcript
2022 Q1
16 May 22
SYRS
Earnings call transcript
2021 Q4
15 Mar 22
SYRS
Earnings call transcript
2021 Q3
5 Nov 21
SYRS
Earnings call transcript
2021 Q2
8 Aug 21
SYRS
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
4
Richard A Young
19 Sep 23
4
Mark J Alles
19 Sep 23
4
SRINIVAS AKKARAJU
19 Sep 23
4
Gerald E Quirk
14 Sep 23
4
David Roth
2 Aug 23
144
Notice of proposed sale of securities
31 Jul 23
4
Eric R Olson
18 Jul 23
144
Notice of proposed sale of securities
17 Jul 23
4
Richard A Young
2 Jun 23
4
PETER WIRTH
2 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 118.53 mm | 118.53 mm | 118.53 mm | 118.53 mm | 118.53 mm | 118.53 mm |
Cash burn (monthly) | (no burn) | (no burn) | 11.33 mm | 11.89 mm | 7.46 mm | 10.51 mm |
Cash used (since last report) | n/a | n/a | 34.19 mm | 35.87 mm | 22.51 mm | 31.72 mm |
Cash remaining | n/a | n/a | 84.33 mm | 82.66 mm | 96.01 mm | 86.81 mm |
Runway (months of cash) | n/a | n/a | 7.4 | 7.0 | 12.9 | 8.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 5 |
Closed positions | 9 |
Increased positions | 12 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 27.67 bn |
Total shares | 15.60 mm |
Total puts | 0.00 |
Total calls | 80.60 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 2.12 mm | $6.69 bn |
Bain Capital Life Sciences Fund II | 2.12 mm | $0.00 |
Artal | 1.48 mm | $4.65 mm |
Avidity Partners Management | 1.46 mm | $4.61 bn |
Artal International S.C.A. | 1.46 mm | $0.00 |
Ally Bridge MedAlpha Master Fund | 1.44 mm | $0.00 |
Flagship Pioneering | 993.85 k | $3.13 bn |
Samsara BioCapital | 881.45 k | $2.78 bn |
CHI Advisors | 767.45 k | $2.42 bn |
Adage Capital Partners GP, L.L.C. | 721.91 k | $2.27 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Sep 23 | Akkaraju Srinivas | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,666 | 0.00 | 2,666 |
16 Sep 23 | Akkaraju Srinivas | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,666 | 0.00 | 5,334 |
16 Sep 23 | Young Richard A | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,666 | 0.00 | 38,837 |
16 Sep 23 | Young Richard A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,666 | 0.00 | 5,334 |
16 Sep 23 | Alles Mark J | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,666 | 0.00 | 3,666 |
16 Sep 23 | Alles Mark J | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,666 | 0.00 | 5,334 |
12 Sep 23 | Gerald E Quirk | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
31 Jul 23 | David Roth | Common Stock | Sell | Dispose S | No | Yes | 3.95 | 7,348 | 29.02 k | 0 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
11 Aug 23
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
9 Aug 23
Syros Pharmaceuticals Q2 EPS $(1.30) Misses $(1.13) Estimate, Sales $2.83M Miss $3.50M Estimate
8 Aug 23
Earnings Scheduled For August 8, 2023
8 Aug 23
Earnings Outlook For Syros Pharmaceuticals
7 Aug 23
Press releases
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 Sep 23
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
8 Aug 23
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Aug 23
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
1 Aug 23
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Jul 23